News | Radiation Therapy | November 02, 2022

Prospective multi-center international randomized controlled trial will compare 2-year overall survival in pancreatic cancer patients receiving post-chemotherapy ablative MRIdian SMART vs. chemotherapy alone


November 2, 2022 — ViewRay, Inc.  announced the launch of a phase III randomized controlled trial titled "Locally Advanced Pancreatic cancer treated with ABLATivE stereotactic MRI-guided adaptive radiation therapy" – also known as LAP-ABLATE. LAP-ABLATE will compare stand-alone multi-agent chemotherapy, which is the current standard of care for patients with locally advanced pancreatic cancer, to patients receiving a combination of chemotherapy and 5-fraction MRIdian SMART (stereotactic MR-guided adaptive radiotherapy). The study is designed to demonstrate superior overall survival in patients receiving post-chemotherapy MRIdian SMART. The anticipated enrollment target is 267 patients (NCT05585554).  

Although surgery is considered a potentially curative treatment for non-metastatic pancreatic cancer, less than 20 percent of patients are candidates. Of the remaining patients, approximately 40 percent have locally advanced pancreatic cancer (LAPC), and another 40 percent have distant metastases at diagnosis. LAPC is usually not resectable because the tumor encases major abdominal blood vessels.

"This first-of-its-kind prospective multi-center international randomized controlled trial was prompted by the exciting results of several recently published ablative MRIdian SMART studies that demonstrated markedly improved treatment efficacy and reduced toxicity compared to outcomes from non-ablative radiation therapy," said Michael D. Chuong, M.D., lead investigator of the LAP-ABLATE trial and Medical Director of Radiation Oncology at the Miami Cancer Institute, part of Baptist Health South Florida. "While prior studies of chemotherapy plus non-ablative radiation have not shown an improvement over chemotherapy alone for patients with LAPC, we believe MRIdian's advanced capabilities overcome the many limitations of other radiation treatment modalities. Ablative doses with MRIdian SMART can provide pancreatic cancer patients a clinically meaningful improvement in long-term survival while maintaining an excellent quality of life and rarely causing significant side effects."  

Conventional chemotherapy plus non-ablative radiotherapy has not demonstrated improvements to overall survival. Further studies have supported the notion that significantly escalating the radiation dose to an ablative range may improve overall survival. But the feasibility of delivering ablative radiation dose to the pancreas has historically been limited. Previous clinical trials have resulted in a high risk of injury to the stomach and nearby bowel loops, resulting in severe side effects such as pain, bleeding, or obstruction.

"Pancreatic cancer is one of the most challenging diseases to treat, and while currently available therapies can have a meaningful impact for a proportion of patients, they are non-curative for the vast majority," said Martin Fuss, M.D., Chief Medical Officer at ViewRay. "LAP-ABLATE will evaluate the combination of chemotherapy and MRI-guided ablative dose radiation therapy to determine MRIdian's role in improving overall survival outcomes and expanding the treatment options for patients with locally advanced disease."

MRIdian integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track soft-tissue and tumors. By providing real-time continuous tracking of the tumor and organs-at-risk, MRIdian enables automatic gating of the radiation, turning the beam off if the target moves outside user-defined margins. This allows for precise delivery of the prescribed dose to the target while sparing surrounding healthy tissue and critical structures.

"Despite major advances in other oncology indications, treatment options for pancreatic cancer remain severely limited, including for patients with locally advanced disease," said Julie Fleshman, President and CEO of the Pancreatic Cancer Action Network (PanCAN). "At PanCAN we support patient involvement in clinical trials as a way to gain access to some of the best treatment options and most cutting-edge approaches. We're looking forward to the results of the LAP-ABLATE trial and the opportunity to validate a potential breakthrough therapy for this group of patients."

For more information: https://viewray.com/mridian-treatment-centers/

Find more ASTRO22 content here 

Related Content:  

Varian Receives Investigational Device Exemption (IDE) for Flash Technology Clinical Trial, FAST-02 

VIDEO: First FLASH Proton Therapy Trial Completed in Humans  

MRIdian Clinical Studies and Initial MRIdian A3i Clinical Experience to be Highlighted at ASTRO 2022


Related Content

News | Proton Therapy

October 3, 2023 — Mevion Medical Systems, the leading global provider of compact proton therapy solutions, and RaySearch ...

Time October 03, 2023
arrow
News | Radiology Business

October 3, 2023 — The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest ...

Time October 03, 2023
arrow
News | ASTRO

October 3, 2023 — Medical device company GT Medical Technologies, Inc. announced interim findings of a multi ...

Time October 03, 2023
arrow
News | Computed Tomography (CT)

October 3, 2023 — Using previously taken diagnostic computed tomography (CT) scans in place of CT simulation scans to ...

Time October 03, 2023
arrow
News | Lung Imaging

October 2, 2023 — A novel liquid biopsy test may help determine which patients with non-small cell lung cancer that has ...

Time October 02, 2023
arrow
News | Radiation Therapy

October 2, 2023 — A type of head and neck cancer predominantly diagnosed in people who reside in low- and middle-income ...

Time October 02, 2023
arrow
News | Radiation Oncology

October 2, 2023 — Two liquid biopsy tests that look for the presence of human papillomavirus (HPV) in the blood ...

Time October 02, 2023
arrow
News | Prostate Cancer

October 1, 2023 — The presence of a clinical navigator to act as a liaison between people with prostate cancer and the ...

Time October 01, 2023
arrow
News | ASTRO

October 1, 2023 — The 2023 Abstract Award winners have been announced by the American Society for Radiation Oncology ...

Time October 01, 2023
arrow
News | Women's Health

October 1, 2023 — In a first-of-its-kind study, people with breast cancer who underwent implant-based breast ...

Time October 01, 2023
arrow
Subscribe Now